Global Network of Adaptive Clinical Trials Is Helping Fight COVID-19

Learn how Amgen and the newly formed COVID R&D Alliance are leveraging adaptive platform trials to accelerate research to combat the current global pandemic.

In an article published in STAT First Opinion, Amgen’s David Reese and Andy Plump, president of R&D at Takeda, share their perspective on the power of cross-industry collaboration and how adaptive platform trials can help accelerate research to combat the current global pandemic.

Amgen and Takeda, along with more than 20 leading life sciences companies, are working together to identify and accelerate promising therapeutic candidates for COVID-19 and its related symptoms through the newly formed COVID R&D Alliance.

Viruses leverage animal and human networks. With an adaptive research ecosystem, we could begin to match them in speed, mobility, and evolutionary vigor, and ultimately keep the world safe.

Click here to read the STAT op-ed and learn more about our research initiatives.

As the COVID-19 pandemic continues to evolve, we are committed to doing everything we can to keep our staff and their families safe, as well as to help the communities where we live and work reduce the number of people exposed to the virus. We are also committed to continuing to deliver an uninterrupted supply of our medicines for the patients who need them. If you are a patient, medical professional, employee, or member of the community, please see our COVID-19 Information Center page.


Share This Story